Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Three vs 6 months of adjuvant oxaliplatin-based chemotherapy may be sufficient for colon cancer with low risk of recurrence and has the advantage of fewer side effects, according to the IDEA* trial which pooled data from six phase III trials.
The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.
Selective internal radiation therapy (SIRT) did not fare better than sorafenib in terms of overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC), though it appeared to be associated with fewer total adverse events, according to findings of the phase III, multicentre (11 Asia-Pacific countries), open-label SIRveNIB* study.
Human papillomavirus (HPV) vaccination demonstrates efficacy against oral HPV infections among young adults, although the low uptake limits the population-level effectiveness of the vaccine, according to a cross-sectional study presented at the 2017 ASCO Annual Meeting in Chicago.
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.